medtronic plc (MDT:New York)
Transactions by MEDTRONIC PLC (MDT) in the last 6 months
Medtronic plc (NYSE:MDT) signed a definitive agreement to acquire Twelve, Inc. for approximately $460 million on August 25, 2015. Medtronic will pay $408 million at closing and $50 million on achievement of CE Marking. The cash- and debt-free transaction remains subject to customary closing conditions and is expected to close in October 2015. Medtronic expects the net impact from the acquisition to be earnings neutral as the company intends to offset the dilutive impact ...
Medtronic plc (NYSE:MDT) signed a definitive agreement to acquire RF Surgical Systems, Inc. for approximately $240 million on July 13, 2015. The deal is expected to close in August 2015, pending regulatory approvals. Medtronic will report the RF Surgical business as part of its Surgical Solutions division within the Minimally Invasive Technologies Group. The transaction is expected to meet Medtronic's long-term financial metrics for acquisitions, and the annualized earnings ...
Split Rock Partners, LLC
Medtronic plc (NYSE:MDT) acquired CardioInsight Technologies Inc. from Case Technology Ventures, Draper Triangle, LLC, West Capital Advisors, LLC, JumpStart, Inc., Investment Arm, and others for $100 million on June 19, 2015. Consideration consisted of an initial cash payment of $75 million and retirement of a Medtronic loan outstanding to CardioInsight in the amount of $25 million. Medtronic acquired CardioInsight on a debt-free basis in a transaction valued at approximately ...
Draper Triangle, LLC
JumpStart, Inc., Investment Arm
West Capital Advisors, LLC
Medtronic plc (NYSE:MDT) acquired the assets of Aptus Endosystems, Inc. from Heron Capital Equity Partners, Heron Capital Venture Capital, Synergy Life Science Partners, U.S. Venture Partners and others for approximately $110 million on June 19, 2015. The transaction is expected to meet Medtronic's long-term financial metrics for acquisitions, and the annualized earnings impact of this acquisition is not expected to be material. Krystin Hayward and Jeff Warren of GlobeNewswire, ...
Heron Capital Venture Capital
Heron Capital Venture Fund I, L.P.
Longitude Capital Management Co., LLC
Longitude Venture Partners, L.P.
Synergy Life Science Partners
U.S. Venture Partners
Arsenal AAA, LLC announced that it has received funding from Medtronic plc on June 17, 2015. The investor has acquired stake in the company.
St. Jude Medical Inc. (NYSE:STJ) agreed to acquire remaining stake in Spinal Modulation, Inc. from De Novo Ventures, InCube Ventures, LLC, Johnson & Johnson Innovation - JJDC, Inc., Kleiner Perkins Caufield & Byers, Raffles Venture Partners, Medtronic plc (NYSE:MDT), MedVenture Associates V, L.P., managed by MedVenture Associates, The Angels' Forum LLC, The Halo Funds and others for approximately $180 million on April 20, 2015. St. Jude Medical will also make additional ...
DFJ ePlanet Ventures, L.P.
Draper Fisher Jurvetson
InCube Ventures, LLC
Johnson & Johnson Innovation - JJDC, Inc.
Kleiner Perkins Caufield & Byers
MedVenture Associates V, L.P.
Raffles Venture Partners
The Angels' Forum LLC
The Halo Funds
DreaMed Diabete announced that it has received $2 million in an equity round of funding from new investor Medtronic plc on April 6, 2015.
Medtronic plc (NYSE:MDT) acquired Diabeter on April 2, 2015. Amanda Sheldon acted as the public relation advisor and Jeff Warren acted as the investor relation advisor in this transaction.
Medtronic plc (NYSE:MDT) acquired Sophono, Inc. on March 26, 2015. The transaction enables Medtronic's Ear Nose and Throat business to continue its focus on novel therapies and innovative technology solutions and supports Medtronic's therapy innovation strategy. Medtronic will include revenue from the Sophono product line as part of the Surgical Technologies division within the Restorative Therapies Group segment. The transaction is expected to meet Medtronic's long-term ...
Colorado Institute for Drug, Device & Diagnostic Development
Wexford Capital LLC
Wexford Capital, LLC, Private Equity Arm
Semma Therapeutics announced that it has received $44,000,000 in its series A round of funding led by new investor, MPM Capital on March 18, 2015. The transaction included participation from new investors, Arch Venture Partners, L.P., Fidelity Biosciences, and Medtronic plc. The company issued series A preferred stock in the transaction. As a part of the transaction, Robert Millman, Todd Foley, and Jim Scopa of MPM Capital, Steven Knight of Fidelity Biosciences joined ...
|AbbVie Inc||$64.51 USD||+1.37|
|Allergan plc||$312.00 USD||+6.02|
|Amgen Inc||$155.72 USD||+1.74|
|Bristol-Myers Squibb Co||$60.82 USD||+0.79|
|Eli Lilly & Co||$83.74 USD||+2.64|
|View Industry Companies|